Fig. 4From: Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injuryEmpagliflozin suppresses advanced glycation end products (AGE), restores endothelial nitric oxide synthase (eNOS) activation and reduces interstitial and periarterial nitroso-oxidative stress. a Representative micrographs show AGE expression in renal arterioles, assessed by immunofluorescence labeling. The accompanying bar graphs show a semi-quantitative analysis of average immunofluorescence intensities obtained from five randomly selected arterioles (n = 9–11/group). b Western blot analysis shows changes in expression of phospho-eNOSser1177, phospho-eNOST495, and GAPDH. The bar graphs to the right show quantitative analyses of protein expression of these serine (1177) and threonine (495) phosphorylated eNOS proteins normalized to GAPDH. Representative micrographs show 3-nitrotyrosine immunostaining in the (c) interstitium and (d) periarteriolar regions of the kidney (magnification = 4× and 40×, respectively). The accompanying bar graphs show a semi-quantitative analysis of average immunofluorescence staining intensities obtained from five randomly selected areas (n = 6/group). *p < 0.05 vs. CkC; †p < 0.05 vs. DbC. All values are mean ± SEBack to article page